Maximizing Uptake of Breakthrough Medicines across Canada: Lessons from CAR-T Therapy

Thursday, June 1, 2023







Housekeeping



Questions

Submit a question using the Q&A function at any time



Slides

The slides and a webinar recording will be sent via email



Survey

Please take a few minutes to complete the survey that will be sent to attendees this afternoon





I2U - or Idea to Utilization – is an initiative to offer health system leaders across Canada the **knowledge**, **support and information** they need to be better prepared to capture the full value of future breakthrough medicines that emerge from world-class biomedical research.



I2U's Focus: Maximizing the Value of Breakthrough Drugs ofter reimbursement decisions have been made



Our Advisory Board



Dr. Shaan Chugh Medical Director of Solutions, Trillium Health Partners



Martine Elias Executive Director, Myeloma Canada



Zayna Khayat VP of Client Success & Growth, Teledoc Health



Marcel Saulnier Associate, Santis Health; Former ADM, Health Canada



Graham Statt Former ADM, Alberta Ministry of Health and Vice-Chair, pCPA



Helen Stevenson Founder and CEO, Reformulary Group



Dr. Robyn Tamblyn Professor of Medicine and Medical Scientist, McGill University



Today's Panelists







Associate, Santis Health; Former ADM, Health Canada

Martine Elias Executive Director,

Myeloma Canada





Graham Statt

Former ADM, Alberta Ministry of Health and Vice-Chair, pCPA **Caroline Barber** Vice-President of Public Affairs and Government Relations, Novartis Canada



Case Studies: Identifying Key Barriers to Implementation





Current Context on CAR-T Therapy in Canada




CONTEXTUALIZING CAR-T THERAPY Background

- CAR-T Therapy is a type of cell therapy that provides a personalized, target treatment to fight cancer.
- There are currently several commercially available CAR-T therapies for blood cancer indications that have been approved in Canada.
- Given the highly personalized nature of CAR-T Therapy, this class of medicines cannot be delivered through traditional community-based pharmacies and instead requires significant infrastructure and expertise for administration of treatment.



ACCESS IN CANADA Access to Commercial CAR-T Therapies





CONTEXTUALIZING CAR-T THERAPY Implementation Challenges in Canada

1. The Need for Administrative Infrastructure: CAR-T Therapy requires accredited sites with institution-accredited staff with expertise in its delivery.

2. Manufacturing Capabilities of CAR-T Cells: There is further development required for in-house manufacturing before there is widespread access across Canada.



CONTEXTUALIZING CAR-T THERAPY Implementation Challenges in Canada

3. Need for Cold Chain Management Infrastructure: CAR-T cells must be cryopreserved starting from manufacturing facilities, during transport and at treatment centres.

4. Capacity for Post-Infusion Care: There is a need for capacity for potential in-patient admission after patients receive treatment.



Learn More About I2U



